The dosage, timing and duration of tolvaptan administration in Patients Hospitalized for Acute Decompensated Heart Failure

The dosage, timing and duration of tolvaptan administration in Patients Hospitalized for Acute Decompensated Heart Failure - The dosage, timing and duration of tolvaptan administration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014441

Enrollment

100

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

The early group receives tolvaptan (5-7 days) within 2 days of hospital admission and the late group receives tolvaptan(5-7 days) from day 5 or 6 day of hospitalization In case of re-admission within

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients hospitalized with heart failure

Exclusion criteria

Exclusion criteria: Contraindication of usage of tolvaptan

Design outcomes

Primary

Measure	Time frame
Improvement of heart failure, duration of hospitalization, death	—

Secondary

Measure	Time frame
Change of urine volume, vital signs, electrolytes, renal function, costs of diuretics	—

Countries

Japan

Contacts

Public ContactTanaka Nobukiyo

Ichinomiya Nishi Hospital Department of Cardiovascular Medicine

nobukiyo282000@yahoo.co.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026